NCT05729646

Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Perioperative S-1 Plus Oxaliplatin Combined With Toripalimab or Toripalimab Monotherapy Versus S-1 Plus Oxaliplatin for Treatment of dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: a Prospective, Multi-center, Randomized Controlled Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Yu jiren · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is a prospective, multi-center, randomized controlled phase II trial to compare the efficacy of perioperative SOX plus toripalimab, toripalimab monotherapy with SOX regimen in participants with dMMR locally advanced gastric or esophagogastric junction adenocarcinoma

Conditions

• Adenocarcinoma of the Stomach
• Adenocarcinoma of Esophagogastric Junction
• Mismatch Repair Deficiency

Interventions

Type	Name	Description
DRUG	Toripalimab	Perioperative Toripalimab, 240 mg IV infusion
DRUG	Oxaliplatin	Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
DRUG	S1	S-1 orally intake as perioperative chemotherapy

Timeline

• Start date: 2023-05-31
• Primary completion: 2026-02-28
• Completion: 2029-02-28
• First posted: 2023-02-15
• Last updated: 2023-07-25

Locations

8 sites across 1 country: China